Arcus Biosciences Inc - Asset Resilience Ratio
Arcus Biosciences Inc (RCUS) has an Asset Resilience Ratio of 62.29% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Arcus Biosciences Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Arcus Biosciences Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see RCUS current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Arcus Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Arcus Biosciences Inc to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $621.00 Million | 62.29% |
| Total Liquid Assets | $621.00 Million | 62.29% |
Asset Resilience Insights
- Very High Liquidity: Arcus Biosciences Inc maintains exceptional liquid asset reserves at 62.29% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arcus Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Arcus Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Celldex Therapeutics Inc
NASDAQ:CLDX |
Biotechnology | 81.32% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Savara Inc
NASDAQ:SVRA |
Biotechnology | 68.30% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
Annual Asset Resilience Ratio for Arcus Biosciences Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Arcus Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 66.64% | $759.00 Million | $1.14 Billion | -5.36pp |
| 2024-12-31 | 72.00% | $828.00 Million | $1.15 Billion | +14.28pp |
| 2023-12-31 | 57.72% | $632.00 Million | $1.09 Billion | -1.99pp |
| 2022-12-31 | 59.70% | $803.00 Million | $1.34 Billion | +37.63pp |
| 2021-12-31 | 22.07% | $351.39 Million | $1.59 Billion | -49.82pp |
| 2020-12-31 | 71.89% | $555.23 Million | $772.29 Million | +7.73pp |
| 2019-12-31 | 64.17% | $130.33 Million | $203.11 Million | -3.30pp |
| 2018-12-31 | 67.47% | $185.48 Million | $274.93 Million | +26.90pp |
| 2017-12-31 | 40.57% | $77.28 Million | $190.49 Million | +9.82pp |
| 2016-12-31 | 30.75% | $33.74 Million | $109.70 Million | -- |
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, a… Read more